Reslizumab
Reslizumab is a humanized IgG4-κ anti-IL-5 mAb developed by drafting
technology from a rat mAb with high affinity against human IL-5152. Reslizumab binds
to a small region corresponding to amino acids 89-92 of IL-5, which are
critical for binding to IL-5Rα153. Reslizumab
administration results in clinical improvement in asthma and an increase
in FEV1 in patients with eosinophilic counts
> 400 cells/µL compared to placebo153-158. Apparently
contrasting results have been reported on the effects of reslizumab on
the improvement of FEV1 compared to placebo. Although
several studies reported that reslizumab significantly improved
FEV1 compared to placebo154,
157, other investigators found that
reslizumab had no improvement in FEV1 compared to those
receiving placebo 154.
A real-life study recently confirmed the efficacy of reslizumab
treatment in reducing the number of exacerbations and increasing
FEV1 6 months after the beginning of treatment159.